SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Mohab Hassanin, who joined the Company as Clinical Trial Manager.
News
Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Cell Therapy Scientific Advisory Board (SAB). The Cell Therapy SAB is comprised of industry and academic leaders in… Click here to view original post… […]
News
Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reported financial results for the second quarter of 2021. Oncternal management will host a webcast today at 5:00 p.m. ET to provide a business… Click here to view original post… […]
News
Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the BTIG Virtual Biotechnology Conference being held August 9-10, 2021. Click here to view original post… […]
